# N-Boc-cis-4-Hydroxy-D-proline

| | |
|---|---|
| **Cat. No.:** | HY-W002887 |
| **CAS No.:** | 135042-12-5 |
| **Molecular Formula:** | $C_{10}H_{17}NO_5$ |
| **Molecular Weight:** | 231.25 |
| **Target:** | ADC Linker; PROTAC Linkers |
| **Pathway:** | Antibody-drug Conjugate/ADC Related; PROTAC |
| **Storage:** | Powder -20°C 3 years<br>4°C 2 years<br>In solvent -80°C 6 months<br>-20°C 1 month |



## SOLVENT & SOLUBILITY

**In Vitro**

DMSO : 100 mg/mL (432.43 mM; Need ultrasonic)

| Preparing Stock Solutions | Solvent / Mass / Concentration | 1 mg | 5 mg | 10 mg |
|---|---|---|---|---|
| | 1 mM | 4.3243 mL | 21.6216 mL | 43.2432 mL |
| | 5 mM | 0.8649 mL | 4.3243 mL | 8.6486 mL |
| | 10 mM | 0.4324 mL | 2.1622 mL | 4.3243 mL |

Please refer to the solubility information to select the appropriate solvent.

**In Vivo**

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 2.5 mg/mL (10.81 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: ≥ 2.5 mg/mL (10.81 mM); Clear solution
3. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 2.5 mg/mL (10.81 mM); Clear solution

## BIOLOGICAL ACTIVITY

**Description**

N-Boc-cis-4-Hydroxy-D-proline is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). N-Boc-cis-4-Hydroxy-D-proline is also a alkyl chain-based PROTAC linker that can be used in the Synthesis of ADCs or PROTACs.

**$IC_{50}$ & Target**

Non-cleavable

**In Vitro**

ADCs are comprised of an antibody to which is attached an ADC cytotoxin through an ADC linker[1].
PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for

the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## REFERENCES


[1]. Beck A, et al. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017;16(5):315-337.

[2]. Nalawansha DA, et al. PROTACs: An Emerging Therapeutic Modality in Precision Medicine. Cell Chem Biol. 2020;27(8):998-985.





Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA